Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2953–2976 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: PD-1inhibitor - LVGN 3616, CD 40 Agonist - LVGN 7409; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pyruvate Dehydrogenase Complex Deficiency
Interventions: Dichloroacetate (DCA), Placebo, Genotype; Drug · Other · Genetic
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Isatuximab, Lenalidomide; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
Interventions: Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin; Dietary Supplement · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Stroke, Patent Foramen Ovale, PFO
Interventions: Investigational PFO Closure Device, Standard of Care PFO Closure Device; Device
Lead sponsor: Occlutech International AB; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Stanford, California • Thousand Oaks, California + 20 more

Conditions: Overweight, Obesity
Interventions: Online Weight Management Program with Coaching and Patient Navigator Support; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 20 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Subjects, Lean Trained Subjects, Overweight and Obesity
Interventions: Running Program, Yoga Program; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 40 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Posttraumatic Stress Disorder, Complex Post-Traumatic Stress Disorder
Interventions: Not listed
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Malden, Massachusetts

Conditions: Smoking Cessation; Tobacco Dependence, E-Cig Use, Nicotine Dependence, Other Tobacco Product
Interventions: BREATHE Free Curriculum; Behavioral
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Bortezomib, Dexamethasone, Pelareorep, Pembrolizumab; Drug · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Obesity, Adolescent
Interventions: Guys/Girls Opt for Activities for Life (GOAL); Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 10 Years to 14 Years
Enrollment: 935 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • East Lansing, Michigan

Conditions: Stroke
Interventions: Nitric Oxide; Drug
Lead sponsor: Steven Messe; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 570 participants
Timeline: 2019 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more

Conditions: End Stage Renal Disease
Interventions: there is no intervention; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 21 Years
Enrollment: 150 participants
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Sacituzumab Govitecan, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Mobile, Alabama • Oceanside, California • Clermont, Florida + 12 more

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
Interventions: ABBV-319; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more

Conditions: Dementia
Interventions: CoMPoSER intervention group, Sleep Education; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Amputation, Amputation, Traumatic, Amputation; Traumatic, Hand, Amputation; Traumatic, Limb
Interventions: Clinically prescribed prosthesis, Experimental prosthesis - Wrist rotation + 1-DOF, Experimental prosthesis - Wrist rotation + Wrist flexion +1-DOF, Experimental prosthesis - Wrist rotation + Multi DOF hand, Experimental prosthesis - Wrist rotation + wrist flexion + Multi DOF hand; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Shigellosis
Interventions: bacteriophage, Placebo; Biological · Other
Lead sponsor: Intralytix, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ofatumumab approved dose, Ofatumumab new dose; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 50 more

Conditions: Fistula-in-ano, Draining Wound
Interventions: Kerecis fish skin; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: Semaglutide, Tirzepatide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: BRCA1 Mutation, BRCA2 Mutation
Interventions: Family Letter (Standard of Care), Educational Video, Mailed Saliva Kit for Genetic Testing, Telephone Counseling; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: New York, New York • Durham, North Carolina • Houston, Texas

Conditions: Cervical Carcinoma, Endometrial Carcinoma
Interventions: Hypofractionated Radiation Therapy; Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

CD40 Agonist and PD-1 Inhibitor in HNSCC

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

Elimination of Minimal Residual Disease After Transplant

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

Partnerships for Reducing Overweight and Obesity with Patient-Centered Strategies 2.0

Training Effects on Fuel Metabolism

Using Data Science To Center Patient Perspectives in Mechanism Discovery

BREATHE Free Curriculum

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Guys/Girls Opt for Activities for Life Trial (GOAL) to Increase Young Adolescents' Physical Activity and Healthy Eating

Diffuse Optical Monitoring With Inhaled Nitric Oxide

CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

The Impact of Music Intervention on Sleep

GaMA Metric to Quantify Functional Importance of Various Upper Limb Prosthetic Devices

Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

A Study Of Cryptoglandular Fistula-in-ano And Associated Non-healing Draining Wounds With Kerecis SurgiClose

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

FaCT Trial (Facilitated Cascade Testing Trial)

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer